- Home
- PHAR vs ASPN Comparison
PHAR vs ASPN Comparison
Compare PHAR & ASPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ASPN
- Stock Information
- Founded
- PHAR 1988
- ASPN 2001
- Country
- PHAR Netherlands
- ASPN United States
- Employees
- PHAR N/A
- ASPN N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ASPN RETAIL: Building Materials
- Sector
- PHAR Health Care
- ASPN Consumer Discretionary
- Exchange
- PHAR Nasdaq
- ASPN Nasdaq
- Market Cap
- PHAR 707.9M
- ASPN 638.5M
- IPO Year
- PHAR N/A
- ASPN 2014
- Fundamental
- Price
- PHAR $10.96
- ASPN $7.61
- Analyst Decision
- PHAR Strong Buy
- ASPN Strong Buy
- Analyst Count
- PHAR 3
- ASPN 10
- Target Price
- PHAR $30.00
- ASPN $21.78
- AVG Volume (30 Days)
- PHAR 5.3K
- ASPN 2.1M
- Earning Date
- PHAR 07-31-2025
- ASPN 08-07-2025
- Dividend Yield
- PHAR N/A
- ASPN N/A
- EPS Growth
- PHAR N/A
- ASPN N/A
- EPS
- PHAR N/A
- ASPN N/A
- Revenue
- PHAR $339,836,000.00
- ASPN $436,921,000.00
- Revenue This Year
- PHAR $12.88
- ASPN N/A
- Revenue Next Year
- PHAR $8.54
- ASPN $24.31
- P/E Ratio
- PHAR N/A
- ASPN N/A
- Revenue Growth
- PHAR 22.44
- ASPN 51.90
- 52 Week Low
- PHAR $6.73
- ASPN $4.16
- 52 Week High
- PHAR $12.61
- ASPN $33.15
- Technical
- Relative Strength Index (RSI)
- PHAR 58.06
- ASPN 59.45
- Support Level
- PHAR $9.54
- ASPN $7.36
- Resistance Level
- PHAR $10.46
- ASPN $8.34
- Average True Range (ATR)
- PHAR 0.37
- ASPN 0.48
- MACD
- PHAR 0.10
- ASPN 0.01
- Stochastic Oscillator
- PHAR 81.20
- ASPN 64.15
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ASPN Aspen Aerogels Inc.
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.